SPERO THERAPEUTICS INC (SPRO) Stock Fundamental Analysis

NASDAQ:SPRO • US84833T1034

2.21 USD
-0.01 (-0.45%)
At close: Feb 26, 2026
2.18 USD
-0.03 (-1.36%)
After Hours: 2/26/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall SPRO gets a fundamental rating of 4 out of 10. We evaluated SPRO against 521 industry peers in the Biotechnology industry. SPRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SPRO is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SPRO has reported negative net income.
  • In the past year SPRO has reported a negative cash flow from operations.
  • SPRO had negative earnings in 4 of the past 5 years.
  • In the past 5 years SPRO always reported negative operating cash flow.
SPRO Yearly Net Income VS EBIT VS OCF VS FCFSPRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

  • SPRO's Return On Assets of -80.92% is on the low side compared to the rest of the industry. SPRO is outperformed by 68.14% of its industry peers.
  • SPRO's Return On Equity of -165.46% is on the low side compared to the rest of the industry. SPRO is outperformed by 65.45% of its industry peers.
Industry RankSector Rank
ROA -80.92%
ROE -165.46%
ROIC N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
SPRO Yearly ROA, ROE, ROICSPRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • SPRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRO Yearly Profit, Operating, Gross MarginsSPRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SPRO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SPRO has more shares outstanding
  • SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SPRO Yearly Shares OutstandingSPRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SPRO Yearly Total Debt VS Total AssetsSPRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • SPRO has an Altman-Z score of -10.90. This is a bad value and indicates that SPRO is not financially healthy and even has some risk of bankruptcy.
  • SPRO has a worse Altman-Z score (-10.90) than 74.09% of its industry peers.
  • There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.9
ROIC/WACCN/A
WACC8.69%
SPRO Yearly LT Debt VS Equity VS FCFSPRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • SPRO has a Current Ratio of 3.83. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
  • SPRO has a Current ratio of 3.83. This is comparable to the rest of the industry: SPRO outperforms 45.87% of its industry peers.
  • A Quick Ratio of 3.83 indicates that SPRO has no problem at all paying its short term obligations.
  • The Quick ratio of SPRO (3.83) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.83
SPRO Yearly Current Assets VS Current LiabilitesSPRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • SPRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1228.57%.
  • SPRO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -61.91%.
  • The Revenue has been growing by 21.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.38%
Revenue 1Y (TTM)-61.91%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-59.6%

3.2 Future

  • Based on estimates for the next years, SPRO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.25% on average per year.
  • Based on estimates for the next years, SPRO will show a very strong growth in Revenue. The Revenue will grow by 20.52% on average per year.
EPS Next Y91.97%
EPS Next 2Y59.31%
EPS Next 3Y13.29%
EPS Next 5Y20.25%
Revenue Next Year-34.56%
Revenue Next 2Y-85.67%
Revenue Next 3Y-56.53%
Revenue Next 5Y20.52%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SPRO Yearly Revenue VS EstimatesSPRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
SPRO Yearly EPS VS EstimatesSPRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • SPRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • SPRO is valuated cheaply with a Price/Forward Earnings ratio of 3.23.
  • Based on the Price/Forward Earnings ratio, SPRO is valued cheaper than 99.23% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of SPRO to the average of the S&P500 Index (28.13), we can say SPRO is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.23
SPRO Price Earnings VS Forward Price EarningsSPRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRO Per share dataSPRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • SPRO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as SPRO's earnings are expected to grow with 13.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.31%
EPS Next 3Y13.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SPRO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SPERO THERAPEUTICS INC

NASDAQ:SPRO (2/26/2026, 8:00:02 PM)

After market: 2.18 -0.03 (-1.36%)

2.21

-0.01 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-25
Inst Owners16.1%
Inst Owner Change87.04%
Ins Owners2.43%
Ins Owner Change1.43%
Market Cap124.51M
Revenue(TTM)40.55M
Net Income(TTM)-43.84M
Analysts43.33
Price Target4.08 (84.62%)
Short Float %2.18%
Short Ratio3.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)70.64%
Min EPS beat(2)49.02%
Max EPS beat(2)92.26%
EPS beat(4)3
Avg EPS beat(4)44.13%
Min EPS beat(4)-20.18%
Max EPS beat(4)92.26%
EPS beat(8)6
Avg EPS beat(8)100.4%
EPS beat(12)10
Avg EPS beat(12)186.6%
EPS beat(16)11
Avg EPS beat(16)138.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)87.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)26.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.23
P/S 3.07
P/FCF N/A
P/OCF N/A
P/B 4.7
P/tB 4.7
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)0.68
Fwd EY30.92%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.72
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -80.92%
ROE -165.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.83
Quick Ratio 3.83
Altman-Z -10.9
F-Score3
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.38%
EPS Next Y91.97%
EPS Next 2Y59.31%
EPS Next 3Y13.29%
EPS Next 5Y20.25%
Revenue 1Y (TTM)-61.91%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-59.6%
Revenue Next Year-34.56%
Revenue Next 2Y-85.67%
Revenue Next 3Y-56.53%
Revenue Next 5Y20.52%
EBIT growth 1Y-3984.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-195.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-195.49%
OCF growth 3YN/A
OCF growth 5YN/A

SPERO THERAPEUTICS INC / SPRO FAQ

What is the ChartMill fundamental rating of SPERO THERAPEUTICS INC (SPRO) stock?

ChartMill assigns a fundamental rating of 4 / 10 to SPRO.


Can you provide the valuation status for SPERO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SPERO THERAPEUTICS INC (SPRO). This can be considered as Fairly Valued.


What is the profitability of SPRO stock?

SPERO THERAPEUTICS INC (SPRO) has a profitability rating of 0 / 10.


What is the financial health of SPERO THERAPEUTICS INC (SPRO) stock?

The financial health rating of SPERO THERAPEUTICS INC (SPRO) is 6 / 10.